Prevention of Silent Cerebral Thromboembolism by Oral Anticoagulation With Dabigatran After Pulmonary Vein Isolation for Atrial Fibrillation
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.
Also called NCT02067182
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 200 participants
- Sponsor
- Registry
-
NCT02067182 -
2013-003492-35
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Germany
- Registry status
- Completed
Technical summary
Registry record NCT02067182. Randomized; no masking; primary purpose treatment. Start 2015-08 (registry gives no type); primary completion 2020-09-15 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Prevention of Silent Cerebral Thromboembolism by Oral Anticoagulation With Dabigatran After Pulmonary Vein Isolation for Atrial Fibrillation
- Acronym
- ODIn-AF
- Condition
- Atrial Fibrillation
- Condition
- Cardioembolic Events
- Condition
- Oral Anticoagulation
- Intervention (Drug)
- Dabigatran
- Lead sponsor
- Georg Nickenig
- Collaborator
- Boehringer Ingelheim
Record details
- Record id
cardio:ct-nct02067182- Content hash
165dfdc55b7a5254f417a820f19ae55cce33709ded0c4dad7162fc33728f1b93